Endoscopic Eradication of Barrett’s Esophagus
Publication Date: May 17, 2024
Key Points
Key Points
- In patients with Barrett’s esophagus (BE), counsel tobacco cessation and weight loss if overweight.
- Refer patients with dysplastic BE to high-volume endoscopists with expertise in endoscopic eradication therapy (EET), pathologists with expertise in BE neoplasia, with access to multidisciplinary care.
- Histologic diagnosis of BE dysplasia or early cancer should be confirmed by an expert pathologist.
- In patients undergoing management of dysplastic BE, optimize reflux control with medication, lifestyle modifications, and assessing adherence.
- Before embarking on EET, discuss risks and benefits of EET, need for adherence with reflux management, expected outcomes, need for continued surveillance after completion of EET, with adequate time to assess patient values and preferences.
- The goal of EET should be complete eradication of intestinal metaplasia and neoplasia.
- Failure to achieve complete eradication of intestinal metaplasia should prompt reassessment and optimization of reflux control.
- Endoscopists and practices performing EET are encouraged to monitor key outcomes and quality metrics, including complete eradication of intestinal metaplasia and neoplasia and adverse events.
Treatment
Treatmen...
...ndoscopic Eradication Therapy of Barre...
...n 1In individuals with BE with high-grade dy...
...dation 2In individuals with BE with low-grade d...
...tion 3In individuals with NDBE, AGA sugg...
...ation 4In patients undergoing EET,...
...n 5In individuals with BE with visible neopla...